glycoprotein	Clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
glycoprotein	Clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
glycoprotein	diphosphate	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	none	none	none
glycoprotein	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	296	none	D000241
glycoprotein	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	296	none	D000241
glycoprotein	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
glycoprotein	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
glycoprotein	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
glycoprotein	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	none	none	none
Clopidogrel	Plavix	5	7	true	positive	Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.  Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix.  		32968	0	C055162	174742
Clopidogrel	Plavix	5	7	true	positive	Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.  Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix.  		32968	0	C055162	174742
Clopidogrel	Plavix	15	13	false	none	Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  Gender    In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.  12.3 Pharmacokinetics    Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites.  		32968	0	C055162	174742
Clopidogrel	Plavix	15	13	false	none	Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  Gender    In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.  12.3 Pharmacokinetics    Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites.  		32968	0	C055162	174742
Clopidogrel	Plavix	17	19	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%.  		32968	0	C055162	174742
Clopidogrel	Plavix	17	19	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%.  		32968	0	C055162	174742
Clopidogrel	Plavix	17	18	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		32968	0	C055162	174742
Clopidogrel	Plavix	17	18	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		32968	0	C055162	174742
Clopidogrel	Plavix	16	18	false	none	Absorption    After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.  Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		32968	0	C055162	174742
Clopidogrel	Plavix	16	18	false	none	Absorption    After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.  Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		32968	0	C055162	174742
Clopidogrel	Plavix	23	21	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	0	C055162	174742
Clopidogrel	Plavix	23	21	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	0	C055162	174742
Clopidogrel	Plavix	22	21	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	0	C055162	174742
Clopidogrel	Plavix	22	21	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	0	C055162	174742
Clopidogrel	diphosphate	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	2	3	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	2	3	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	diphosphate	5	3	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		32968	none	C055162	none
Clopidogrel	diphosphate	5	3	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		32968	none	C055162	none
Clopidogrel	adenosine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	2	3	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	2	3	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	296	C055162	D000241
Clopidogrel	adenosine	5	3	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		32968	296	C055162	D000241
Clopidogrel	adenosine	5	3	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		32968	296	C055162	D000241
Clopidogrel	p450	34	35	false	none	Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	34	35	false	none	Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	35	35	false	none	Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	35	35	false	none	Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	2	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	2	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	33	35	false	none	12.5 Pharmacogenomics    CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.  Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	33	35	false	none	12.5 Pharmacogenomics    CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.  Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
Clopidogrel	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
Clopidogrel	p450	23	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	none	C055162	none
Clopidogrel	p450	23	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	none	C055162	none
Clopidogrel	p450	22	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	none	C055162	none
Clopidogrel	p450	22	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	none	C055162	none
Clopidogrel	p450	24	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.  		32968	none	C055162	none
Clopidogrel	p450	24	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.  		32968	none	C055162	none
Plavix	creatinine	12	12	false	none	Renally-Impaired Patients    After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.  		0	none	174742	none
Plavix	creatinine	12	12	false	none	Renally-Impaired Patients    After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.  		0	none	174742	none
Plavix	creatinine	13	12	true	positive	Renally-Impaired Patients    After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.  Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  		0	none	174742	none
Plavix	creatinine	13	12	true	positive	Renally-Impaired Patients    After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.  Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  		0	none	174742	none
Plavix	clopidogrel	19	17	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%.  		0	32968	174742	C055162
Plavix	clopidogrel	19	17	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%.  		0	32968	174742	C055162
Plavix	clopidogrel	18	17	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		0	32968	174742	C055162
Plavix	clopidogrel	18	17	false	none	Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		0	32968	174742	C055162
Plavix	clopidogrel	18	16	false	none	Absorption    After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.  Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		0	32968	174742	C055162
Plavix	clopidogrel	18	16	false	none	Absorption    After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.  Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.  Effect of Food    Plavix can be administered with or without food.  		0	32968	174742	C055162
Plavix	clopidogrel	21	23	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		0	32968	174742	C055162
Plavix	clopidogrel	21	23	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		0	32968	174742	C055162
Plavix	clopidogrel	21	22	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		0	32968	174742	C055162
Plavix	clopidogrel	21	22	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		0	32968	174742	C055162
Plavix	clopidogrel	7	5	true	positive	Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.  Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix.  		0	32968	174742	C055162
Plavix	clopidogrel	7	5	true	positive	Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.  Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix.  		0	32968	174742	C055162
Plavix	clopidogrel	13	15	false	none	Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  Gender    In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.  12.3 Pharmacokinetics    Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites.  		0	32968	174742	C055162
Plavix	clopidogrel	13	15	false	none	Hepatically-Impaired Patients    After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.  Gender    In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.  12.3 Pharmacokinetics    Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites.  		0	32968	174742	C055162
Plavix	p450	21	22	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		0	none	174742	none
Plavix	p450	21	22	false	none	Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.  Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		0	none	174742	none
diphosphate	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	296	none	D000241
diphosphate	adenosine	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	296	none	D000241
diphosphate	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	32968	none	C055162
diphosphate	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
diphosphate	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		none	32968	none	C055162
diphosphate	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		none	none	none	none
adenosine	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	3	false	none	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	32968	D000241	C055162
adenosine	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		296	32968	D000241	C055162
adenosine	clopidogrel	3	5	true	positive	The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  		296	32968	D000241	C055162
adenosine	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	none	D000241	none
adenosine	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		296	none	D000241	none
clopidogrel	p450	34	35	false	none	Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	34	35	false	none	Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	35	35	false	none	Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	35	35	false	none	Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.  12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	2	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	2	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	33	35	false	none	12.5 Pharmacogenomics    CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.  Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	33	35	false	none	12.5 Pharmacogenomics    CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.  Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.  Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.  		32968	none	C055162	none
clopidogrel	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	3	2	false	none	12.2 Pharmacodynamics    Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.  The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  		32968	none	C055162	none
clopidogrel	p450	23	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	none	C055162	none
clopidogrel	p450	23	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  		32968	none	C055162	none
clopidogrel	p450	22	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	none	C055162	none
clopidogrel	p450	22	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  		32968	none	C055162	none
clopidogrel	p450	24	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.  		32968	none	C055162	none
clopidogrel	p450	24	22	false	none	Metabolism    Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes.  Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.  Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.  		32968	none	C055162	none
